SignalXSignalX

AKBA Akebia Therapeutics, Inc.

8-K Current Report
Filed: February 26, 2026
Health Care
Pharmaceutical Preparations
Akebia Therapeutics, Inc. Overview

Akebia Therapeutics, Inc. (AKBA) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 earnings released Feb 26, 2026; full results and financials in Exhibit 99.1
  • • Key focus: commercial launch performance of Vafseo® (vadadustat), an oral anemia treatment, plus pipeline updates

Get deeper insights on Akebia Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.